IGI Logo

Launch marks the World’s first biosimilar Antibody Drug Conjugate of Trastuzumab Emtansine. The therapy will be priced at nearly 80% less than the currently available option in the market. Developed in-house, the antibody drug conjugate is considered to be one of the most complex technologies in drug development.

Zydus Cadila, a global innovation driven healthcare company, launched Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) biosimilar and a highly effective drug for treating both Early and Advanced HER2 positive Breast Cancer, under the brand name ‘Ujvira’. HER2 positive Breast Cancer is considered an aggressive form and constitutes 20 to 25% of all Breast Cancers. In a step that can significantly reduce treatment cost by almost 80%, the drug is being offered at Rs. 32495 for a 100 mg vial. The current MRP of existing Trastuzumab Emtansine drug is Rs. 1,59,225 for 100 mg vial. Ujvira will be available in two strengths, 100 mg and 160 mg.

This is a very positive development for the company, it is one of the significant launches that company has done in this quarter. We have a positive outlook toward the company.

Above views are of the author and not of the website kindly read disclaimer